Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nat Cancer ; 3(11): 1300-1317, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36434392

RESUMEN

Five-year survival for human papilloma virus-unrelated head and neck squamous cell carcinomas remain below 50%. We assessed the safety of administering combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1) neoadjuvantly (n = 21) ( NCT03635164 ). The primary endpoint of the study was safety, which was met. Secondary endpoints included radiographic, pathologic and objective response; locoregional control; progression-free survival; and overall survival. Among evaluable patients at an early median follow-up of 16 months (448 d or 64 weeks), overall survival was 80.1% with 95% confidence interval (95% CI) (62.0%, 100.0%), locoregional control and progression-free survival were 75.8% with 95% CI (57.5%, 99.8%), and major pathological response or complete response was 75% with 95% exact CI (51.6%, 100.0%). For patients treated with 24 Gy, 89% with 95% CI (57.1%, 100.0%) had MPR or CR. Using high-dimensional multi-omics and spatial data as well as biological correlatives, we show that responders had: (1) an increase in effector T cells; (2) a decrease in immunosuppressive cells; and (3) an increase in antigen presentation post-treatment.


Asunto(s)
Neoplasias de Cabeza y Cuello , Infecciones por Papillomavirus , Radiocirugia , Humanos , Neoplasias de Cabeza y Cuello/terapia , Terapia Neoadyuvante/efectos adversos , Infecciones por Papillomavirus/complicaciones , Radiocirugia/efectos adversos , Carcinoma de Células Escamosas de Cabeza y Cuello/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA